Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

BAIYU Holdings shares touched a 52-week low as the stock returned to Nasdaq, over a month after the Securities and Exchange Commission temporarily suspended trading. However, shares could possibly ...

Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...

BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply chain service provider, today announced that it has filed timely a formal ...

Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...

CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...

SHENZHEN, China, Oct. 8, 2024 /PRNewswire/ -- BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply chain service provider ...

Short interest in Baiyu Holdings Inc (NASDAQ:BYU) decreased during the last reporting period, falling from 1.21M to 1.20M. This put 2.6% of the company's publicly available shares short.

BAIYU Holdings shares touched a 52-week low as the stock returned to Nasdaq, over a month after the Securities and Exchange Commission temporarily suspended trading. However, shares could possibly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...